Pharming Group NV (PHARM) — Net Asset Quality Index
Pharming Group NV (PHARM) has a Net Asset Quality Index of 55.9% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €473.79 Million minus total liabilities of €209.14 Million yields net assets of €264.64 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read Pharming Group NV (PHARM) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Pharming Group NV Net Asset Quality Index Over Time (2005–2024)
This chart shows how Pharming Group NV's Net Asset Quality Index has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the index stands at 55.9%, representing net assets of €264.64 Million against total assets of €473.79 Million EUR. For live market cap and overall valuation, see PHARM market cap overview.
Annual Net Asset Quality Index for Pharming Group NV (2005–2024)
The table below presents the year-by-year Net Asset Quality Index for Pharming Group NV from 2005 to 2024, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Pharming Group NV PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 55.4% | €214.16 Million | €386.88 Million | €172.72 Million | ▲ +8.9 pp |
| 2023 | 46.5% | €198.05 Million | €426.34 Million | €228.28 Million | ▼ -1.6 pp |
| 2022 | 48.1% | €204.64 Million | €425.80 Million | €221.16 Million | ▼ -0.5 pp |
| 2021 | 48.6% | €192.72 Million | €396.90 Million | €204.19 Million | ▲ +4.7 pp |
| 2020 | 43.8% | €183.73 Million | €419.12 Million | €235.39 Million | ▼ -2.0 pp |
| 2019 | 45.9% | €117.26 Million | €255.63 Million | €138.38 Million | ▲ +17.1 pp |
| 2018 | 28.8% | €70.64 Million | €245.45 Million | €174.81 Million | ▲ +17.5 pp |
| 2017 | 11.3% | €22.56 Million | €199.38 Million | €176.82 Million | ▼ -10.4 pp |
| 2016 | 21.7% | €28.89 Million | €133.34 Million | €104.45 Million | ▼ -19.7 pp |
| 2015 | 41.3% | €26.06 Million | €63.06 Million | €37.00 Million | ▼ -12.2 pp |
| 2014 | 53.6% | €36.29 Million | €67.75 Million | €31.46 Million | ▲ +37.6 pp |
| 2013 | 16.0% | €6.92 Million | €43.37 Million | €36.45 Million | ▲ +61.4 pp |
| 2012 | -45.4% | €-10.12 Million | €22.28 Million | €32.40 Million | ▼ -40.6 pp |
| 2011 | -4.8% | €-1.54 Million | €32.01 Million | €33.55 Million | ▼ -31.9 pp |
| 2010 | 27.1% | €13.43 Million | €49.59 Million | €36.16 Million | ▲ +3.3 pp |
| 2009 | 23.8% | €19.07 Million | €80.07 Million | €60.99 Million | ▲ +5.1 pp |
| 2008 | 18.7% | €17.45 Million | €93.40 Million | €75.96 Million | ▼ -11.7 pp |
| 2007 | 30.3% | €50.58 Million | €166.72 Million | €116.14 Million | ▼ -32.7 pp |
| 2006 | 63.0% | €65.78 Million | €104.37 Million | €38.59 Million | ▼ -20.1 pp |
| 2005 | 83.1% | €34.04 Million | €40.96 Million | €6.93 Million | — |